6Y6H
Crystal structure of STK17b (DRAK2) in complex with UNC-AP-194 probe
Summary for 6Y6H
| Entry DOI | 10.2210/pdb6y6h/pdb |
| Descriptor | Serine/threonine-protein kinase 17B, 2-[6-(1-benzothiophen-2-yl)thieno[3,2-d]pyrimidin-4-yl]sulfanylethanoic acid, 1,2-ETHANEDIOL, ... (4 entities in total) |
| Functional Keywords | kinase, kinase inhibitor, pkis, drak2, chemical probe, structural genomics, structural genomics consortium, sgc, transferase |
| Biological source | Homo sapiens (Human) |
| Total number of polymer chains | 1 |
| Total formula weight | 37995.88 |
| Authors | Chaikuad, A.,Arrowsmith, C.H.,Edwards, A.M.,Bountra, C.,Drewry, D.,Knapp, S.,Structural Genomics Consortium (SGC) (deposition date: 2020-02-26, release date: 2020-03-11, Last modification date: 2024-01-24) |
| Primary citation | Picado, A.,Chaikuad, A.,Wells, C.I.,Shrestha, S.,Zuercher, W.J.,Pickett, J.E.,Kwarcinski, F.E.,Sinha, P.,de Silva, C.S.,Zutshi, R.,Liu, S.,Kannan, N.,Knapp, S.,Drewry, D.H.,Willson, T.M. A Chemical Probe for Dark Kinase STK17B Derives Its Potency and High Selectivity through a Unique P-Loop Conformation. J.Med.Chem., 63:14626-14646, 2020 Cited by PubMed Abstract: STK17B is a member of the death-associated protein kinase family and has been genetically linked to the development of diverse diseases. However, the role of STK17B in normal and disease pathology is poorly defined. Here, we present the discovery of thieno[3,2-d] pyrimidine (), a high-quality chemical probe for this understudied "dark" kinase. is an ATP-competitive inhibitor that showed remarkable selectivity over other kinases including the closely related STK17A. X-ray crystallography of and related thieno[3,2-d]pyrimidines bound to STK17B revealed a unique P-loop conformation characterized by a salt bridge between R41 and the carboxylic acid of the inhibitor. Molecular dynamic simulations of STK17B revealed the flexibility of the P-loop and a wide range of R41 conformations available to the apo-protein. The isomeric thieno[2,3-d]pyrimidine () was identified as a negative control compound. The >100-fold lower activity of on STK17B was attributed to the reduced basicity of its pyrimidine N1. PubMed: 33215924DOI: 10.1021/acs.jmedchem.0c01174 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (1.95 Å) |
Structure validation
Download full validation report
